Prim, S.A (PRM) Fair Value & Analysis
Healthcare · ES · Market cap €230M
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −2.6% over the past month.
Price vs Fair Value (12 months)
12‑month range €10.89 – €13.37 · fair‑value band €12.26 – €26.97 · the €12.85 price screens below the €18.99 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Prim, S.A (PRM) currently trades at €12.85, while our model-based Fair Value estimate is €18.99 — implying the stock looks roughly 47.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Prim, S.A generated revenue of €252M at a net margin of 6.6%. Revenue grew 9.9% year over year. It earns a return on equity of 12.5%. The balance sheet holds a net cash position of €2.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Prim, S.A. operates as a health technology, mobility, and health care products provider in Spain. The company offers collar, clavicle, armsling, hand and finger, shoulder, elbow, and wrist products. Its lower limbs products include calf brace, thigh, hip, knee, ankle, and foot related products. The company provides shoulder and back supports, bands, corsets, hyperextension braces, and thoracic protectors under the airtex PRO, bruxi calm, fisionprim, newfeet, ORTHOPrim, PRIM, PRIMcare, respira PLUS, airMed, airtex, aqtivo skin, aqtivo sport, comforGel, comforGel Lady, comforSil, ESSENCIAL, mottio sport range, my PRIM Kids, Neoprair, ONE SIZE, Primespine, and OLIUM brand names. It operates PrimAcademy, an offline and digital training platform. Prim, S.A. was founded in 1870 and is headquartered in Móstoles, Spain.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Prim, S.A reported revenue of €252M in FY2025 versus €169M in FY2021, a compound +10.6%/yr. Reported net income was €16.7M in FY2025, compounding −1.1%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prim, S.A (PRM) undervalued?
What is the fair value of PRM?
What is the quality score of PRM?
What is the revenue of Prim, S.A (PRM)?
What is the net profit margin of PRM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.